Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 21, Issue 124, 2012, Pages 147-151

  Richeldi, Luca ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cochrane Collaboration; Idiopathic pulmonary fibrosis; Meta analysis; Pirfenidone

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; GAMMA1B INTERFERON; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PIRFENIDONE; PLACEBO; WARFARIN;

DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MORTALITY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERFERON-GAMMA; PYRIDONES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84861862524     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00000912     Document Type: Review

References (29)

1. Cochrane AL. Effectiveness and Efficiency. Random Reflections on Health Services. London, Royal Society of Medicine, 1972.
2. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011; 377: 1760-1769.
3. Mulrow CD. Rationale for systematic reviews. BMJ 1994; 309: 597-599.
4. Bravata DM, Smith-Spangler C, Sundaram V, et al. Using pedometers to increase physical activity and improve health. JAMA 2007; 298: 2296-2304.
5. Antman EM, Lau J, Kupelnick B, et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992; 268: 240-248.
6. King TE Jr, Costabel U, Cordier J-F, et al. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
7. Richeldi L, Davies HR, Spagnolo P, et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3: CD002880.
8. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3: CD003134.
9. Johnson MA, Kwan S, Snell NJC, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
10. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
11. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 220-225.
12. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-1269.
13. Richeldi L, Davies HR, Spagnolo P, et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3: CD002880.
14. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9: CD003134.
15. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
16. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
17. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
18. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
19. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
20. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
21. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
22. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebocontrolled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
23. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
24. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
25. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
26. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
27. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27: 1227-1234.
28. Bria E, Gralla RJ, Raftopoulos H, et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: metaanalysis of randomized clinical trials. Lung Cancer 2009; 63: 50-57.
29. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.